Gapping up
In reaction to strong earnings/guidance: UCTT +24.7%, CARA +19.9%, VGGL +16.3%, FTK +14.2%, ASPS +13.5%, SNDK +12.6%, AFOP +12.3%, AFOP +12.3%, LOGI +11.9%, FTNT +11.1%, CRUS +10.6%, MRGE +10.1%, STM +7.5%, CS +7.4%, CY +6.3%, INFN +6%, FFIV +5.8%, CLB +5.8%, LUV +4.6%, USG +4.5%, AOS +4.4%, LVS +3.7%, ZHNE +3.4%,VRX +3.4%, DWCH +3.3%, GPI +3.2%, CVTI +2.8%, UA +2.8%, BMY +2.8%, KKR +2.7%, RTN +2.6%, FBHS +2.5%, NEM +2.3%, UAL +2.3%, MLNX +2.2%, EFX +1.7%, HNI +1.7%, UL +1.7%, DOW +1.7%, CAKE +1.6%, LLY +1.5%, SCSS +1.4%, OII +1.4%, PDS +1.4%, IMAX +1%, HBAN +0.9%
M&A news: MU +2.4% (discusses comments from Holdings exec who says company is still in takeover talks with MU), PSO +2.2% (confirmed that it is in advanced discussions regarding the potential disposal of FT Group)
Select metals/mining stocks trading higher: IAG +6.3%, AUY +4.2%, GFI +4.1%, CLF +2.8%, AU +2.8%, GG +2.5%
Other news: ITEK +60.6% (announces the Phase 3 development strategy of Trabodenoson), CUR +10.1% (announces that a US District Court has dismissed StemCells' (STEM) patent infringement case with prejudice), CI +5.1% (WSJ reporting that co is close to being acquired by Anthem (ANTM) for ~$187 per share), PACD +3.9% (discloses updated 2015 guidance in July investor update), CLBS +3.2% (receives notice of an award from the National Eye Institute of the National Institutes of Health for a project to investigate 3D retinal constructs for vision restoration in patients with age-related macular degeneration), WYNN +2.7% (following LVS results), SURG +2.6% (Synergetics Announces an Early Renewal of the Supply Agreement With Stryker ), GTE +2.6% (announced normal course issuer bid; co would be able to purchase for cancellation up to approximately 5% of its issued and outstanding shares of common stock for a one year period at prevailing market prices), SRPT +2.5% (announced New England Journal of Medicine publication of Phase 1 data of Marburg drug candidate AVI-7288; no clinical or toxicologic safety concerns), CUDA +2.3% (following FTNT / FFIV results), MGM +2% (following LVS results), ACFC +1.3% (disclosed receipt of a written notice of termination of the Supervisory Agreement with the Board of Governors of the Federal Reserve System)
Analyst comments: ARMH +3.7% (upgraded to Buy at Charles Stanley), EMC +1% (upgraded to Outperform from Market Perform at Wells Fargo
)
In reaction to strong earnings/guidance: UCTT +24.7%, CARA +19.9%, VGGL +16.3%, FTK +14.2%, ASPS +13.5%, SNDK +12.6%, AFOP +12.3%, AFOP +12.3%, LOGI +11.9%, FTNT +11.1%, CRUS +10.6%, MRGE +10.1%, STM +7.5%, CS +7.4%, CY +6.3%, INFN +6%, FFIV +5.8%, CLB +5.8%, LUV +4.6%, USG +4.5%, AOS +4.4%, LVS +3.7%, ZHNE +3.4%,VRX +3.4%, DWCH +3.3%, GPI +3.2%, CVTI +2.8%, UA +2.8%, BMY +2.8%, KKR +2.7%, RTN +2.6%, FBHS +2.5%, NEM +2.3%, UAL +2.3%, MLNX +2.2%, EFX +1.7%, HNI +1.7%, UL +1.7%, DOW +1.7%, CAKE +1.6%, LLY +1.5%, SCSS +1.4%, OII +1.4%, PDS +1.4%, IMAX +1%, HBAN +0.9%
M&A news: MU +2.4% (discusses comments from Holdings exec who says company is still in takeover talks with MU), PSO +2.2% (confirmed that it is in advanced discussions regarding the potential disposal of FT Group)
Select metals/mining stocks trading higher: IAG +6.3%, AUY +4.2%, GFI +4.1%, CLF +2.8%, AU +2.8%, GG +2.5%
Other news: ITEK +60.6% (announces the Phase 3 development strategy of Trabodenoson), CUR +10.1% (announces that a US District Court has dismissed StemCells' (STEM) patent infringement case with prejudice), CI +5.1% (WSJ reporting that co is close to being acquired by Anthem (ANTM) for ~$187 per share), PACD +3.9% (discloses updated 2015 guidance in July investor update), CLBS +3.2% (receives notice of an award from the National Eye Institute of the National Institutes of Health for a project to investigate 3D retinal constructs for vision restoration in patients with age-related macular degeneration), WYNN +2.7% (following LVS results), SURG +2.6% (Synergetics Announces an Early Renewal of the Supply Agreement With Stryker ), GTE +2.6% (announced normal course issuer bid; co would be able to purchase for cancellation up to approximately 5% of its issued and outstanding shares of common stock for a one year period at prevailing market prices), SRPT +2.5% (announced New England Journal of Medicine publication of Phase 1 data of Marburg drug candidate AVI-7288; no clinical or toxicologic safety concerns), CUDA +2.3% (following FTNT / FFIV results), MGM +2% (following LVS results), ACFC +1.3% (disclosed receipt of a written notice of termination of the Supervisory Agreement with the Board of Governors of the Federal Reserve System)
Analyst comments: ARMH +3.7% (upgraded to Buy at Charles Stanley), EMC +1% (upgraded to Outperform from Market Perform at Wells Fargo
)